This is a big problem — it factored into the Food and Drug Administration's (FDA) decision to reject an MDMA-assisted therapy for PTSD this summer. These shortcomings need to be overcome for ...

That could help establish that the power of MDMA lies in its synergy with trauma-focused therapy. THE BASICS There are other flaws in the FDA’s reasoning, to the extent it can be inferred based ...

Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.

The 90-subject study found that after three MDMA-assisted therapy sessions, 67% of participants with PTSD no longer qualified for that diagnosis, while 88% experienced a significant reduction in ...

to further study the effectiveness and safety of its psychedelic formulation. This would require additional funding as well as a number of... and (5) a full array of tailored corporate ...

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, ...

Psychedelics are being tested as add-ons to psychotherapy, but in trials, there's little detail about how the therapy is actually conducted, Dr. Albino Oliveira-Maia says.